Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Other Working Capital Changes (2024 - 2025)

Indivior Pharmaceuticals (INDV) has 2 years of Other Working Capital Changes data on record, last reported at -$7.0 million in Q3 2025.

  • For Q3 2025, Other Working Capital Changes fell 275.0% year-over-year to -$7.0 million; the TTM value through Sep 2025 reached -$26.0 million, changed N/A, while the annual FY2024 figure was -$377.0 million, 190.19% down from the prior year.
  • Other Working Capital Changes reached -$7.0 million in Q3 2025 per INDV's latest filing, up from -$49.0 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $18.0 million in Q1 2025 and bottomed at -$396.0 million in Q1 2024.